Pelago Bioscience

Pelago Bioscience is a fast-growing drug discovery focused contract research organisation (“CRO”) with a service offering centred around its patented Cellular Thermal Shift Assay (“CETSA”) technology. CETSA provides value to customers in accelerating drug discovery projects given its unique ability to quantify a drug compound’s target engagement / how well a compound binds to its intended target in whole-cell physiological conditions. The company serves a growing global customer base of reputable pharmaceutical and biotech companies (c. 50% US) from its state-of-the-art laboratory in Stockholm and currently employs 45 FTEs. The business model combines customised CRO services based on the CETSA technology with license agreements, where leading big pharma companies use the CETSA technology inhouse.